Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 485

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 12
Chunk 485
---
,113,752
    (11) 
     60.8%
  
    Other 5% Stockholders: 

    Claes Wahlestedt, M.D., Ph.D. 
     3,318,583
    (12) 
     10.0 
  
    Shaun Brothers 
     2,025,553
    (13) 
     6.1 

116

    *
    less
    than 1%.

    (1)
    The
    percentages in the table have been calculated based on 33,103,860 shares of our common stock outstanding on March 12, 2025. To
    calculate a stockholder’s percentage of beneficial ownership, we include in the numerator and denominator the common stock
    outstanding and all shares of our common stock issuable to that person in the event of the exercise of outstanding options and other
    derivative securities owned by that person which are exercisable within 60 days of March 12, 2025. Common stock options and
    derivative securities held by other stockholders are disregarded in this calculation. Therefore, the denominator used in calculating
    beneficial ownership among our stockholders may differ. Unless we have indicated otherwise, each person named in the table has sole
    voting power and sole investment power for the shares listed opposite such person’s name.

    (2)
    Includes
    2,003,678 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (3)
    Includes
    1,245,098 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (4)
    Includes
    666,420 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (5)
    Includes
    870,871 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (6)
    Includes 1,171,688 shares of common stock that may be acquired within 60
days of March 28, 2025 upon exercise of vested options.

    (7)
    Includes
    193,737 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options